Arcturus Therapeutics (ARCT)

• Market cap: $466M
• 1 day: -3.80%
• 5 days: 0.53%
• 1 month: -3.37%
• 3 months: -9.65%
• 6 months: -58.43%
• Year to date: -47.96%
• 1 year: -28.22%
• 5 years: 70.16%
• 10 years: 429.85%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

Employees: 180

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

45% more call options, than puts

Call options by funds: $5.34M | Put options by funds: $3.68M

14% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 49

3.43% less ownership

Funds ownership: 100.52% [Q2] → 97.1% (-3.43%) [Q3]

4% less funds holding

Funds holding: 169 [Q2] → 163 (-6) [Q3]

8% less capital invested

Capital invested by funds: $659M [Q2] → $609M (-$49.9M) [Q3]

20% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 30

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $63 266% upside
• Avg. target: $63 266% upside
• High target: $63 266% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 65% 1-year accuracy 71 / 109 met price target	266% upside $63	Buy Reiterated	8 Nov 2024
HC Wainwright & Co. Ed Arce 65% 1-year accuracy 71 / 109 met price target	266% upside $63	Buy Reiterated	1 Oct 2024